Airsupra (albuterol and budesonide) Inhalation Aerosol

Date of Approval: January 10, 2023
Company: AstraZeneca Pharmaceuticals LP
Treatment for: Asthma

Airsupra (albuterol / budesonide) is a newer combination inhaler used to prevent and treat asthma attacks in adults. This medication works to lower lung inflammation and open up the airways to help you breathe better. Airsupra (albuterol / budesonide) is a rescue inhaler, which means it shouldn't be used daily to prevent asthma.

SE: Jittery feeling as it is part albuterol, bronchodilator. Thrush, which is a fungal (yeast) infection in the mouth/tongue, due to the corticosteroid component in this drug. Make sure to have the resident take drinks of water or rinse out mouth after administration.

Cost: $188

Brenzavvy (bexagliflozin) Tablets

Date of Approval: January 20, 2023
Company: TheracosBio, LLC
Treatment for: Diabetes, Type 2

Brenzavvy (bexagliflozin) It works in the kidneys to prevent the absorption of sugar back into your body. This helps your body get rid of excess blood sugar through your urine. By doing so, Brenzavvy (bexagliflozin) lowers your blood sugar levels.

SE: Watch for

Severe allergic reaction: swelling in the face, throat, tongue, or mouth; rash; trouble breathing
High ketone levels in the blood: nausea, vomiting, stomach pain, tiredness, thirsty, dry mouth, fruity breath, trouble breathing

Cost: $50 per 30 day supply

Jesduvroq (daprodustat) Tablets

Date of Approval: February 1, 2023
Company: GlaxoSmithKline
Treatment for: Anemia Associated with Chronic Renal Failure

Jesduvroq (daprodustat) is an oral tablet indicated for the treatment of anemia due to chronic kidney disease (CKD) in adults who have been receiving dialysis for at least four months.

SE:

JESDUVROQ increases the risk of thrombotic vascular events, including major adverse cardiovascular events (MACE).

Cost: $1,064 for 1 month supply

Vowst (fecal microbiota spores, live-brpk) Capsules - formerly SER-109

Date of Approval: April 26, 2023
Company: Seres Therapeutics, Inc.
Treatment for: Prevention of Recurrent Clostridioides difficile Infection

Vowst (fecal microbiota spores, live-brpk) is an oral microbiome therapeutic indicated to prevent the recurrence of Clostridioides difficile infection (CDI) in individuals 18 years of age and older following antibacterial treatment for recurrent CDI.

Yes you read that right, fecal aka BM spores! It has long been known that replacing good bacteria in the gut is the best way to treat D-diff.

SE: abdominal distension (31.1%), fatigue (22.2%), constipation (14.4%), chills (11.1%), and diarrhea (10.0%). The gut biome of the recipient will depend upon the constipation or diarrhea.

Cost: A regime of Vowst is .... hold on to your wallet, $17,500. That is some expensive poop!

TRYVIO (aprocitentan) tablets

Date of Approval: November 15, 2024

Company: Idorsia Pharmaceuticals

Treatment for: HTN

Tryvio (aprocitentan) is an endothelin receptor antagonist (ERA). It blocks the action of endothelin-1, a substance in the body that narrows the blood vessels and causes high blood pressure. Blocking the action of this substance relaxes the blood vessels in the body, which lead to lower blood pressure and easier blood flow to the heart.

S.E.

Most common:

Edema (fluid buildup in the body, swelling; 9%)
Anemia (4%)

Serious SE:

Fluid buildup in the body: shortness of breath; swelling in the legs, ankles, or feet; irregular heartbeat; chest pain; not able to exercise; tiredness; unusual weight gain
Liver injury: loss of appetite, nausea, vomiting, stomach pain in the upper right side, dark urine, fever, yellowing of the skin or whites of the eyes
Anemia (low red blood cell count): tiredness, shortness of breath, irregular heartbeat, dizziness, chest pain, pale skin
Allergic reaction: rash, red skin, swelling

Cost: $800. per 30 tablets (1xday)

Inpefa (sotagliflozin) Tablets

Date of Approval: May 26, 2023
Company: Lexicon Pharmaceuticals, Inc.
Treatment for: Heart Failure

Inpefa (sotagliflozin) is a sodium-glucose cotransporter 2 (SGLT2) inhibitor used in the treatment of heart failure. is an oral prescription medicine used to reduce the risk of death due to heart problems (cardiovascular death), hospitalization for heart failure, and urgent visits to the doctor for heart failure in adults with:

heart failure (when the heart is weak and cannot pump enough blood to the rest of your body), or
type 2 diabetes, chronic kidney disease, and other cardiovascular risk factors.

SE: Urinary tract infection, volume depletion, diarrhea, hypoglycemia, and dizziness.

Cost: $650 per month

Lodoco (colchicine) Tablets

Date of Approval: June 16, 2023
Company: AGEPHA Pharma USA, LLC
Treatment for: Cardiovascular Risk Reduction

Lodoco (colchicine) is an alkaloid indicated to reduce the risk of myocardial infarction (MI), stroke, coronary revascularization, and cardiovascular death in adult patients with established atherosclerotic disease or with multiple risk factors for cardiovascular disease.

Lodoco is the first drug approved to target inflammation that is an underlying cause of atherosclerotic cardiovascular disease. It can be used alone or in combination with cholesterol-lowering medications.

Colchicine is a well-established molecule and generic colchicine that is used at high doses for the treatment of gout. Lodoco has been reformulated in a lower dose specifically for long-term use in cardiovascular disease patients. Lodoco 0.5 mg tablets are a once-daily tablet and will be available in the second half of 2023.

SE: Avoid taking grapefruit!

nausea, vomiting, stomach pain; or
diarrhea.
muscle pain

Drug/Drug interactions: These drugs could cause interactions:

cyclosporine;
nefazodone;
tipranavir;
clarithromycin or telithromycin;
itraconazole or ketoconazole; or
HIV or AIDS medicine - atazanavir, darunavir, fosamprenavir, indinavir, lopinavir, nelfinavir, ritonavir, or saquinavir.

Cost: around $250 month